Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 17/20 | 0.51 |
| ▸ | CTSK | P43235 | 15/20 | 0.51 |
| ▸ | CTSL | P07711 | 3/20 | 0.51 |
| ▸ | CTSB | P07858 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14838007 | 1.00 | CTSS (0.51) | CTSSCTSKCTSLCTSB | |
| SCHEMBL24014614 | 1.00 | CTSS (0.51) | CTSSCTSKCTSLCTSB | |
| SCHEMBL16119271 | 1.00 | CTSS (0.51) | CTSSCTSKCTSLCTSB | |
| SCHEMBL1645980 | 0.87 | CTSS (0.56) | CTSSCTSKCTSLCTSB | |
| SCHEMBL1645984 | 0.87 | CTSS (0.56) | CTSSCTSKCTSLCTSB | |
| SCHEMBL28417635 | 0.86 | CTSS (0.49) | CTSSCTSKCTSLCTSB | |
| SCHEMBL19606035 | 0.86 | CTSS (0.49) | CTSSCTSKCTSLCTSB | |
| SCHEMBL23392338 | 0.86 | CTSK (0.42) | CTSSCTSKCTSLCTSB | |
| SCHEMBL23392337 | 0.86 | CTSK (0.42) | CTSSCTSKCTSLCTSB | |
| SCHEMBL6168157 | 0.82 | CTSK (0.48) | CTSSCTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115073347-A | Preparation method of lactam ring pharmaceutical intermediate | 浙江江北药业有限公司 | 2022-09-20 | — | — | CN | claimed |
| CN-116283706-B | Nemactetvir intermediate Process for the preparation of intermediates | 厦门蔚嘉制药有限公司 | 2025-06-03 | — | — | CN | disclosed |
| CN-116685576-A | Cysteine protease inhibitors and methods of use thereof | 美商帕迪斯生物科学公司 | 2023-09-01 | — | — | CN | disclosed |
| CN-116396191-A | Preparation method of N-tert-butoxycarbonyl-L-glutamic acid dimethyl ester derivative | 阜阳欣奕华制药科技有限公司 | 2023-07-07 | — | — | CN | disclosed |
| CN-116332801-A | Preparation method of N-tert-butoxycarbonyl-L-glutamic acid dimethyl ester derivative | 阜阳欣奕华制药科技有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-116283706-A | Preparation method of Nemactetvir intermediate | 厦门蔚嘉制药有限公司 | 2023-06-23 | — | — | CN | disclosed |
| WO-2023065667-A1 | NOVEL DEUTERATED BENZOTHIAZOLE COMPOUND AND PREPARATION METHOD THEREFOR AND COMPOSITION AND APPLICATION THEREOF | 广州谷森制药有限公司 | 2023-04-27 | — | — | WO | disclosed |
| CN-115322130-A | Preparation of (S) -2- (BOC-amino) -3- [ (S) -2-oxo-3-pyrrolidinyl ] propionic acid methyl ester | 南京正济医药研究有限公司 | 2022-11-11 | — | — | CN | disclosed |
| CN-114057702-B | Novel inhibitor of coronavirus main protease and preparation method and application thereof | 四川大学 | 2022-09-30 | — | — | CN | disclosed |
| CN-115073347-A | Preparation method of lactam ring pharmaceutical intermediate | 浙江江北药业有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-114432301-A | Covalent inhibitor derivative and application thereof in treating virus infection | 北京大学 | 2022-05-06 | — | — | CN | disclosed |
| CN-114057702-A | Novel inhibitor of coronavirus main protease and preparation method and application thereof | 四川大学 | 2022-02-18 | — | — | CN | disclosed |
| US-7462594-B2 | Peptide-like compounds that inhibit coronaviral 3CL and flaviviridae viral proteases | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-12-09 | — | — | US | disclosed |
| US-20080125375-A1 | PROTEASE INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-05-29 | — | — | US | disclosed |
| US-7304088-B2 | Peptide like compounds for treating coronavirus or hepatitis C virus; severe acute respiratory distress syndrome | TAIGEN BIOTECHNOLOGY (TW) | 2007-12-04 | — | — | US | disclosed |
| US-20050143319-A1 | Protease inhibitors | TAIGEN BIOTECHNOLOGY | 2005-06-30 | — | — | US | disclosed |
| US-20050143320-A1 | Protease inhibitors | TAIGEN BIOTECHNOLOGY | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143319-A1 | Protease inhibitors | PREP, SERPINB1, SPINT2 | CTSS 46/4885CTSK 94/4885CTSL 35/4885 |
| US-20050143320-A1 | Protease inhibitors | PREP, SPINT2, SERPINB1 | CTSS 47/4885CTSK 94/4885CTSL 33/4885 |
| US-20080125375-A1 | PROTEASE INHIBITORS | PREP, SERPINB1, SPINT2 | CTSS 46/4885CTSK 94/4885CTSL 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.